Retrospective Analysis of Kampo Medicine's Role in Mitigating Endocrine Therapy Side Effects in Breast Cancer Patients: A Pilot Investigation - Scorecard - MDSpire
Advertisement
Retrospective Analysis of Kampo Medicine's Role in Mitigating Endocrine Therapy Side Effects in Breast Cancer Patients: A Pilot Investigation
Clinical Scorecard: Retrospective Analysis of Kampo Medicine's Role in Mitigating Endocrine Therapy Side Effects in Breast Cancer Patients: A Pilot Investigation
At a Glance
Category
Detail
Condition
Endocrine therapy-related side effects in breast cancer patients
Key Mechanisms
Kampo medicines alleviate menopausal-like symptoms caused by endocrine therapy
Target Population
Breast cancer patients undergoing endocrine therapy
Care Setting
Kampo Support Clinic at Japanese Red Cross Ishinomaki Hospital
Key Highlights
75% of patients reported NRS scores of 3 or less after 6 months
KBG/KBGY significantly associated with symptom relief (Hazard Ratio 4.18)
Vasomotor, motor/sensory, and psychiatric symptoms accounted for 90% of complaints
KBG/KBGY led to faster overall symptom improvement compared to other Kampo medicines
Study conducted from July 2017 to June 2024 with 53 patients enrolled
Guideline-Based Recommendations
Diagnosis
Evaluate symptom severity using Numerical Rating Scale (NRS)
Monitor symptoms associated with breast cancer and hormone therapy
Management
Prescribe Kampo medicines tailored to individual symptoms
Consider KBG/KBGY for managing hot flashes and other menopausal symptoms
Monitoring & Follow-up
Assess symptom improvement at 3, 6, and 12 months
Collect data on adverse events at each visit
Risks
Exclude patients with severe liver dysfunction, renal failure, or uncontrolled diabetes mellitus
Patient & Prescribing Data
Breast cancer patients receiving endocrine therapy
Kampo medicines, particularly KBG/KBGY, are effective in reducing side effects
Clinical Best Practices
Utilize a multidisciplinary approach involving Kampo specialists
Tailor Kampo medicine prescriptions based on individual patient symptoms
Regularly monitor patient progress and adjust treatment as necessary
A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.
